MiSight myopia control contact lens slows fastest progressing eyes the most
Click Here to Manage Email Alerts
SAN DIEGO — Data from a 7-year clinical study of the MiSight 1-Day myopia control lens indicated that the fastest progressing eyes slowed the most during treatment, as reported at a virtual press conference held during Academy 2022.
Paul Chamberlain, BSc, MCOptom, director of research programs at CooperVision, said during the academy-sponsored press conference that the ongoing clinical trial showed that CooperVision’s MiSight contact lenses slowed progression by 52% when compared with the group wearing spherical contact lenses.
“However, it reveals nothing about individualized treatment,” he said. “In the data from our treated group from all 6 years, you can see an enormous amount of variability in our sample. It leads to the question: Does faster growth during treatment indicate treatment failure? Conversely, in patients with slower progression, does it indicate the treatment worked better?”
Chamberlain said those questions cannot be answered with standard cohort analysis, but the “unique study design offers us a window into this possibility.”
The statistical analysis revealed two main points, Chamberlain said.
“Over 90% were fit by a model indicating significant slowing of growth,” he said. “Ten percent showed significant growth and indicated they were nonresponders.”
The researchers then conducted an analysis on the initial responder group.
“We took untreated eye growth predictions for all quartiles and overlayed them to eye growth once they were treated with MiSight. There’s a drastic difference: The fastest progressing myopes and the slowest progressing myopes, when untreated, indicated the faster progressing myopes showed the lowest amount of slowing.”
He further explained: “Ninety percent of eyes responded to MiSight, and 10% were considered nonresponders. The fastest progressing eyes slowed the most during treatment, and the slower-growing eyes stopped growing during treatment.”
The researchers stated in the study abstract: “Because of the wide range of progression rates, assessment of treatment efficacy for an individual can benefit by comparison of progression under treatment with progression prior to the start of treatment.”
Collapse
Chamberlain P, et al. Assessment of MiSight 1 Day myopia control treatment in fast and slow progressors. Presented at: Academy; Oct. 26-29, 2022; San Diego.
Read more about
Click Here to Manage Email Alerts